Rachel Abbott was named chief scientific officer of Pan Cancer T, a biotech spin-off from Erasmus MC focused on the discovery and development of next-generation TCR-T therapies against solid tumors.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe